ArticleAdvanced genetics (Hoboken, N.J.)2025
Delving Into the Dialogue between Epigenetic Modifications and Immunometabolism in Cancer.
Article in Advanced genetics (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic Reprogramming ofCancer communications (London, England) · 2026Article
- Delving Into the Dialogue between Epigenetic Modifications and Immunometabolism in Cancer.Advanced genetics (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor immunometabolism and epigenetic modifications are intricately linked in reshaping the tumor microenvironment, with their crosstalk offering novel insights into cancer biology. Nutrient deprivation and metabolic byproducts drive metabolic reprogramming in immune cells, where metabolites act as epigenetic modulators to regulate immune-related gene expression and influence immune cell activation, differentiation, and functional states. The cellular complexity, dynamic interactions, and spatiotemporal heterogeneity of the tumor microenvironment pose significant challenges to current studies. Emerging technologies such as single-cell sequencing, spatial omics, and artificial intelligence provide powerful tools to address these complexities. This perspective discusses the crosstalk between tumor immunometabolism and epigenetic modifications, while also exploring how the emerging technologies may advance mechanistic insights and therapeutic innovation in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.